Inozyme Pharma’s (INZY) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Inozyme Pharma (NASDAQ:INZY) in a report released on Wednesday morning,Benzinga reports. They currently have a $14.00 price objective on the stock. HC Wainwright also issued estimates for Inozyme Pharma’s Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.62) EPS, FY2025 earnings at ($1.74) EPS and FY2026 earnings at ($1.89) EPS.

Several other brokerages have also commented on INZY. Wedbush restated an “outperform” rating and issued a $12.00 price objective (down from $15.00) on shares of Inozyme Pharma in a report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a report on Friday, October 25th. Jefferies Financial Group reaffirmed a “buy” rating and set a $17.00 target price (up previously from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th. Finally, Stifel Nicolaus began coverage on shares of Inozyme Pharma in a research note on Thursday, September 12th. They set a “buy” rating and a $16.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $15.71.

Inozyme Pharma Stock Performance

Shares of INZY opened at $4.02 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 9.84. Inozyme Pharma has a one year low of $2.71 and a one year high of $7.80. The company has a 50-day simple moving average of $5.10 and a two-hundred day simple moving average of $4.93. The firm has a market capitalization of $258.24 million, a PE ratio of -2.58 and a beta of 1.54.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. On average, analysts anticipate that Inozyme Pharma will post -1.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Inozyme Pharma

Several institutional investors and hedge funds have recently made changes to their positions in INZY. Deerfield Management Company L.P. Series C bought a new stake in shares of Inozyme Pharma during the second quarter valued at approximately $52,000. Meeder Asset Management Inc. bought a new stake in shares of Inozyme Pharma during the second quarter valued at approximately $68,000. Values First Advisors Inc. bought a new stake in shares of Inozyme Pharma during the second quarter valued at approximately $76,000. SG Americas Securities LLC bought a new stake in shares of Inozyme Pharma during the third quarter valued at approximately $81,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Inozyme Pharma during the second quarter valued at approximately $84,000. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.